TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24880136
Drug: Probiotic (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Lactobacillus salivarius PS2) administered for 21 days
Study: 24881994
Drug: Hypertension (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension (blood pressure ≥140/90 mm Hg or those receiving blood pressure-lowering drugs)
Study: 24882673
Drug: Enzalutamide 160mg
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160mg orally daily
Study: 24883065
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of baseline FGF21 levels with dynamic changes in glucose and insulin levels during OGTT
Study: 24884512
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (5 g/d of fish oil supplement containing 1.9-2.2 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid) for 6 weeks
Study: 24884694
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment of cardiovascular risk factors over 3 months, maintained for 2 years.
Study: 24884782
Drug: Conventional glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucocorticoid replacement therapy
Study: 24885258
Drug: HER2-targeted therapies
Normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HER2-targeted therapies
Study: 24885755
Drug: IOERT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOERT with a median dose of 15 Gy, median electron energy of 6 MeV, median cone size of 9 cm
Study: 24885755
Drug: Postoperative EBRT
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative EBRT with a median dose of 46 Gy after IOERT or 60 Gy without IOERT
Study: 24885755
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy including IOERT and postoperative EBRT
Study: 24886078
Drug: Sugar absorption
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar absorption test in FD patients
Study: 24886078
Drug: Sugar absorption
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar absorption test in controls
Study: 24886192
Drug: Dietary ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary ascorbic acid intake (100 mg/day higher)
Study: 24886512
Drug: Everolimus treatment
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus treatment with positive expression of phospho-mTOR
Study: 24886512
Drug: Everolimus treatment
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus treatment with positive expression of phospho-S6RP
Study: 24886512
Drug: Everolimus treatment
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus treatment with negative expression of phospho-4EBP1 and phospho-AKT
Study: 24888813
Drug: GAA peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAA peptide vaccination with EphA2, IL-13Rα2, and survivin peptides emulsified in Montanide-ISA-51, administered subcutaneously every 3 weeks for eight courses, followed by booster vaccinations every 6 weeks.
Study: 24889179
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) at 250 mg/day for 24 weeks
Study: 24890385
Drug: TGF-β antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TGF-β antagonists
Study: 24890858
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m² IV on d1, 4, 8, 11) and Doxorubicin (15 mg/m² IV on d1, 8) in 21-day cycles
Study: 24891274
Drug: Decitabine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (15 mg/m2 iv) and Vorinostat (230 mg/m2 PO div BID) followed by chemotherapy (vincristine, prednisone, PEG-asparaginase, doxorubicin)
Study: 24891429
Drug: Mefloquine/artesunate (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine/artesunate (fixed-dose combination) administered orally once daily for 3 days
Study: 24892263
Drug: Etanercept (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (0.4 mg/kg, maximum 25 mg/dose) twice weekly for 4 to 8 weeks
Study: 24892263
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (control)
Study: 24892422
Drug: Gammaplex (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gammaplex (5% Intravenous Immunoglobulin, IVIg) at a dosage of 1 g/kg on two consecutive days
Study: 24892422
Drug: Gammaplex (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gammaplex (5% Intravenous Immunoglobulin, IVIg)
Study: 24894084
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDCT) with two cycles of Epirubicin and Paclitaxel (Epi-Tax), followed by three consecutive HDCT cycles (one with Paclitaxel/Thiotepa (Thio-Tax) and two with Ifosfamide-Carboplatin-Etoposide regimen)
Study: 24895163
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PESP presence and LVEF ≤ 35%
Study: 24898091
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose (ULD) IL-2
Study: 24898305
Drug: Ombrabulin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (35 mg/m(2), 30-min infusion, day 1 every 3 weeks) with cisplatin (75 mg/m(2), day 1) and docetaxel (75 mg/m(2), day 2)
Study: 24898305
Drug: Ombrabulin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (35 mg/m(2), 30-min infusion, day 1 every 3 weeks) with carboplatin (AUC6) and paclitaxel (200 mg/m(2), day 2)
Study: 24898305
Drug: Ombrabulin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (35 mg/m(2))
Study: 24898305
Drug: Cisplatin/docetaxel or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/docetaxel or carboplatin/paclitaxel (standard doses)
Study: 24898549
Drug: RG7155 (anti-CSF-1R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7155 (anti-CSF-1R antibody)
Study: 24900938
Drug: Daily interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interruption of continuous sedative and opioid infusion
Study: 24901360
Drug: Neoadjuvant gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant gemcitabine 1000 mg/m intravenously over 100 minutes and oxaliplatin 80 mg/m intravenously over 2 hours, every 2 weeks.
Study: 24901360
Drug: Adjuvant gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant gemcitabine 1000 mg/m intravenously over 30 minutes days 1, 8, and 15 every 4 weeks.
Study: 24902119
Drug: Ulcerogenic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulcerogenic medication
Study: 24903189
Drug: Imipenem 750
Normalized name: CILASTATIN NA 750MG/IMIPENEM 750MG/VIL INJ IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem 750 mg every 6 hours
Study: 24903189
Drug: Imipenem 1000
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem 1000 mg every 8 hours
Study: 24903189
Drug: Imipenem 1000
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem 1000 mg every 6 hours
Study: 24903629
Drug: Lestaurtinib 80
Normalized name: Lestaurtinib
DrugBank: Lestaurtinib (DB06469)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lestaurtinib 80 mg twice daily for 18 weeks
Study: 24903795
Drug: Intermittent regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent regimen of rifampin (RMP), pyrazinamide (PZA), and ethambutol (EMB) administered BIW or TIW for 6 months after initial daily doses.
Study: 24904120
Drug: Oral ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ixazomib at maximum tolerated dose (MTD) of 2.97 mg/m(2) given weekly for 3 of 4 weeks.
Study: 24904120
Drug: Oral ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ixazomib at MTD of 2.97 mg/m(2).
Study: 24905490
Drug: Pegylated-interferon/ribavirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated-interferon/ribavirin therapy
Study: 24905490
Drug: IL28B rs12979860
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL28B rs12979860 CC SNP
Study: 24905490
Drug: ApoH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApoH and IL28B CC SNP
Study: 24906637
Drug: Canakinumab (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (initial dose 150 mg or 300 mg, escalating up to 600 mg every 4 weeks)
Study: 24906637
Drug: Canakinumab (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (at maximum dose)
Study: 24907635
Drug: Tremelimumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (15 mg/kg) plus gemcitabine (1000 mg/m² on days 1, 8, and 15 of each 28-day cycle)
Study: 24907635
Drug: Tremelimumab (6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (6, 10, or 15 mg/kg) plus gemcitabine
Study: 24912489
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg PO daily) and Everolimus (10 mg PO daily)
Study: 24912660
Drug: Intestinal uptake
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestinal uptake of p-cresol (measured by 24 h urinary excretion of PCS)
Study: 24912660
Drug: Higher urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher urinary excretion of PCS (per 100 μmol increase)
Study: 24912660
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of PCS (in multivariate analysis)
Study: 24913040
Drug: 10-item survey
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-item survey administered to patients
Study: 24913066
Drug: Vandetanib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (300 mg daily for a maximum of 10 weeks)
Study: 24913999
Drug: Antiplatelet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet and anticoagulant therapy strategies
Study: 24914044
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (cohort 1)
Study: 24914044
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (cohort 2)
Study: 24914044
Drug: Lenalidomide 15
Normalized name: lenalidomide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 15 mg/day plus Sunitinib 37.5 mg/day (cohort 3)
Study: 24914044
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (MTD)
Study: 24914044
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day
Study: 24914120
Drug: Voriconazole and
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole and anidulafungin combination therapy
Study: 24914120
Drug: Anidulafungin treatment
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anidulafungin treatment duration
Study: 24916038
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy using ex vivo-expanded cytokine-induced killer (CIK) cells, administered intravenously 10 times, every week for 5 weeks and then every other week for 10 weeks.
Study: 24916038
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy using ex vivo-expanded cytokine-induced killer (CIK) cells.
Study: 24916770
Drug: Navitoclax 325
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax 325 mg co-administered with gemcitabine 1,000 mg/m(2) (21-day dosing schedule)
Study: 24916770
Drug: Navitoclax doses
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax doses escalated from 150 to 425 mg
Study: 24916770
Drug: Navitoclax 325
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax 325 mg with gemcitabine 1,000 mg/m(2)
Study: 24916908
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy preparation through TIPS trial
Study: 24917966
Drug: Antibiotics (H.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (H. pylori-positive patients)
Study: 24917966
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg b.d. for 7 days, followed by 40 mg o.d. for 8 weeks (all patients)
Study: 24918167
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment in patients with SLCO1B1 genotype rs4149056T>C
Study: 24919462
Drug: Dacetuzumab (SGN-40),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacetuzumab (SGN-40), 8 mg/kg/week, administered intravenously for up to 12 cycles
Study: 24920166
Drug: Clock Drawing
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clock Drawing Test (CDT) administered at baseline and annually thereafter
Study: 24920586
Drug: Single-agent ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent ixazomib 0.24 to 2.23 mg/m(2) (days 1, 4, 8, 11; 21-day cycles)
Study: 24920586
Drug: Single-agent ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent ixazomib 0.24 to 2.23 mg/m(2)
Study: 24920921
Drug: Concurrent thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent thoracic radiotherapy and erlotinib
Study: 24923356
Drug: Osteoprotegerin (OPG)
Normalized name: Osteoprotegerin recombinant
DrugBank: AMGN-0007 (DB06511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoprotegerin (OPG) levels in Turner syndrome on antihypertensive medication
Study: 24923792
Drug: DMPA users
Normalized name: DMPA
DrugBank: Zytron (DB11768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA users with calcium intake ≥ 1 g/day
Study: 24924750
Drug: Blank solutions
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank solutions with mineral oil
Study: 24925526
Drug: Fluconazole (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (0.4 µmol·min(-1)·l(-1))
Study: 24925526
Drug: N(G)-monomethyl-L-arginine (L-NMMA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-monomethyl-L-arginine (L-NMMA, 8 µmol/min)
Study: 24926953
Drug: Metreleptin (0.06-0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (0.06-0.24 mg/kg/d) administered for 24 months
Study: 24927856
Drug: Otlertuzumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otlertuzumab (10 or 20 mg/kg) in combination with rituximab (375 mg/m(2)) and bendamustine (90 mg/m(2)); administered IV on days 1 and 15 for up to six 28-day cycles.
Study: 24927856
Drug: Otlertuzumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otlertuzumab (10 or 20 mg/kg) in combination with rituximab and bendamustine;
Study: 24927856
Drug: Otlertuzumab in
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Otlertuzumab in combination with rituximab and bendamustine;
Study: 24928772
Drug: carlumab +
Normalized name: Carlumab
DrugBank: Carlumab (DB12718)
Approvals — FDA: no, EMA: no, PMDA: no
Description: carlumab + chemotherapy (all arms)
Study: 24929258
Drug: Normal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Normal progesterone levels (≤4.77 nmol/L or ≤1.5 ng/mL)
Study: 24929258
Drug: Elevated progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Elevated progesterone levels (>4.77 nmol/L or >1.5 ng/mL)
Study: 24929484
Drug: Volatile organic
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile organic compounds (VOCs) in bile analyzed using selected ion flow tube mass spectrometry (SIFT-MS).
Study: 24932181
Drug: Montelukast monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast monotherapy
Study: 24932181
Drug: Montelukast add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast add-on therapy
Study: 24934522
Drug: Elevated brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated brain natriuretic peptide (>21 pg/mL) and low Child Health Questionnaire physical summary score (<44)
Study: 24934522
Drug: Arrhythmia requiring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arrhythmia requiring treatment
Study: 24935348
Drug: Fractional sodium
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional sodium excretion
Study: 24939214
Drug: Famitinib 25
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famitinib 25 mg/d
Study: 24939214
Drug: Famitinib 25
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famitinib 25 mg/d with elevated TSH
Study: 24944232
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) 50 mg plus abacavir/lamivudine (600/300 mg) once daily
Study: 24944546
Drug: Acute sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute sodium citrate supplementation (0.5 g kg(-1) administered 120 min pre-trial)
Study: 24944546
Drug: Chronic sodium
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic sodium citrate supplementation (0.1 g∙kg(-1) for three days and 0.3 g kg(-1) on the fourth day 120 min pre-trial)
Study: 24944934
Drug: Oral anti-diabetic
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-diabetic drugs (OADs)
Study: 24944934
Drug: Insulin (±OADs)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (±OADs)
Study: 24944934
Drug: Barriers to
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barriers to insulin therapy
Study: 24948692
Drug: Oral forodesine
Normalized name: Forodesine
DrugBank: Forodesine (DB06185)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral forodesine at a dose of 200 mg daily
Study: 24949622
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavior therapy (ICBT) for 12 weeks with therapist support.
Study: 28858443
Drug: Citalopram monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram monotherapy
Study: 24950779
Drug: Flutamide (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (125 mg/day for 6 weeks)
Study: 24950912
Drug: Prospective home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective home monitoring based on daily assessment of FEV1 and electronic symptom score
Study: 24952265
Drug: 10-week aerobic
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10-week aerobic exercise program (cycling twice a week for an hour)
Study: 24952730
Drug: Novel combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel combination therapies targeting AKT/PI3K pathways
Study: 24952730
Drug: Sunitinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib and regorafenib (VEGFR targeting drugs)
Study: 24952730
Drug: CTLA4 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTLA4 and PD-1/PD-L1 antibodies
Study: 24953566
Drug: nab-paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel 100 mg/m² days 1 and 8, cisplatin 75 mg/m² day 1, 5-fluorouracil 1000 mg/m²/day for 96 hours days 1-4, every 3 weeks for three cycles
Study: 24953566
Drug: Concurrent carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concurrent carboplatin (AUC 1.5 weekly) with radiation therapy (70 Gy/35 fractions)
Study: 24954791
Drug: Degarelix (240mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (240mg starting dose, then 80mg once a month for 6 months)
Study: 24956535
Drug: RBP4 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP4 levels in HGCS (51.44 ± 16.23 mg/L)
Study: 24956535
Drug: Omentin-1 levels
Normalized name: benztropine mesylate 1 MG/ML [Cogentin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omentin-1 levels in HGCS (490.41 ± 172 ng/ml)
Study: 24957163
Drug: CCRT (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT (two cycles of the DEP regimen every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk)
Study: 24957163
Drug: CCRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT plus consolidation chemotherapy
Study: 24957534
Drug: Mifepristone (200mg)
Normalized name: mifepristone 200 MG
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (200mg) followed by Misoprostol (800μg buccal)
Study: 24958808
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of zoledronic acid
Study: 24960544
Drug: Cholecalciferol (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (10,000 IU weekly)
Study: 24961662
Drug: Simeprevir (TMC435)
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir (TMC435) 100 mg once daily with PEG IFN-α-2b/RBV
Study: 24963043
Drug: Carfilzomib 56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib 56 mg/m2
Study: 24963043
Drug: Carfilzomib 56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib 56 mg/m2 + Dexamethasone (20 mg)
Study: 24963497
Drug: Low-dose decitabine-based
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine-based chemoimmunotherapy